Wenzhe Teng1, Hu Chen1, Siyao Shi1, Yin Wang2, Kangyao Cheng2. 1. Shanghai University of Traditional Chinese Medicine. 2. School of Nursing, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Abstract
BACKGROUND: The purpose of this study is to determine the therapeutic efficacy of bi-level continuous positive airway pressure (BIPAP) intervention in patients with type II respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease (COPD). METHODS: This review will only include randomized controlled trials (RCTs). The search strategy will be applied to 4 Chinese databases: China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Science and Technology Journal Database (VIP), and Chinese Biomedical Literature Database (SinoMed); and 5 foreign literature databases: PubMed, Cochrane Library, Springer, EBSCO, and Web of Science. RCTs published from inception to October 2020 will be included. The 2 researchers will independently screen and extract the data and assess quality. The main results obtained through blood gas analysis and equipment observation, heterogeneity assessment, sensitivity analysis, funnel chart synthesis, data synthesis, and grouping analysis will be carried out using Review Manager 5.4 software. The trial sequential analysis will be completed using TSA v0.9 developed by the CTU at the Copenhagen Clinical Trial Center. RESULTS: In the current meta-analysis, we will provide more practical and targeted results for the therapeutic efficacy of BIPAP in patients with type II respiratory failure due to acute exacerbation of COPD. CONCLUSION: This study will provide new evidence for the therapeutic efficacy of BIPAP in patients with type II respiratory failure due to acute exacerbation of COPD. REGISTRATION NUMBER: INPLASY2020110003 (DOI:10.37766/inplasy2020.11.0003).
BACKGROUND: The purpose of this study is to determine the therapeutic efficacy of bi-level continuous positive airway pressure (BIPAP) intervention in patients with type II respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease (COPD). METHODS: This review will only include randomized controlled trials (RCTs). The search strategy will be applied to 4 Chinese databases: China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Science and Technology Journal Database (VIP), and Chinese Biomedical Literature Database (SinoMed); and 5 foreign literature databases: PubMed, Cochrane Library, Springer, EBSCO, and Web of Science. RCTs published from inception to October 2020 will be included. The 2 researchers will independently screen and extract the data and assess quality. The main results obtained through blood gas analysis and equipment observation, heterogeneity assessment, sensitivity analysis, funnel chart synthesis, data synthesis, and grouping analysis will be carried out using Review Manager 5.4 software. The trial sequential analysis will be completed using TSA v0.9 developed by the CTU at the Copenhagen Clinical Trial Center. RESULTS: In the current meta-analysis, we will provide more practical and targeted results for the therapeutic efficacy of BIPAP in patients with type II respiratory failure due to acute exacerbation of COPD. CONCLUSION: This study will provide new evidence for the therapeutic efficacy of BIPAP in patients with type II respiratory failure due to acute exacerbation of COPD. REGISTRATION NUMBER: INPLASY2020110003 (DOI:10.37766/inplasy2020.11.0003).
Authors: Miguel Carrera; José M Marín; Antonio Antón; Eusebi Chiner; Maria L Alonso; Juan F Masa; Ramón Marrades; Ernest Sala; Santiago Carrizo; Jordi Giner; Elia Gomez-Merino; Joaquin Teran; Carlos Disdier; Alvar G N Agustí; Ferran Barbé Journal: J Crit Care Date: 2009-01-17 Impact factor: 3.425
Authors: H Gunen; S S Hacievliyagil; F Kosar; L C Mutlu; G Gulbas; E Pehlivan; I Sahin; O Kizkin Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Daniel del Castillo; Emilia Barrot; Elena Laserna; Remedios Otero; Aurelio Cayuela; José Castillo Gómez Journal: Med Clin (Barc) Date: 2003-05-10 Impact factor: 1.725